HER2-TARGETED THERAPIES

According to a recent study, among women who receive adjuvant trastuzumab treatment for HER2-positive breast cancer (both left- and right-sided disease), those who also received radiation therapy, anthracycline treatment, or a combination of the two may experience a persistent post-treatment decline in left ventricular ejection fraction, regardless of age, race, stage, hormone receptor status, duration of treatment, diabetes mellitus, and hypertension.